Older renal cell cancer patients experience increased rates of venous thromboembolic events: a retrospective cohort study of SEER-Medicare data

Table 1 Unadjusted incidence rates of VTEs among older RCC patients, before and after RCC diagnosis SEER-Medicare Data (1991–2003) ^a

n = 11,950 RCC Patients	Incidence 12 months before RCC diagnosis	Incidence 12 months after RCC diagnosis
DVT^a
n/person-years^b	380/11,785	990/9,150
Rate/1,000 ^c	32.2 (29.1-35.7)	108.2 (101.6-115.2)
Rate ratio (after vs. before) ^d	--	3.4 (3.0-3.8)
PE^a
n/person-years^b	95/11,912	286/9,536
Rate/1,000 ^c	8.0 (6.5-9.8)	30.0 (26.6-33.7)
Rate ratio (after vs. before) ^d	--	3.8 (3.0-4.7)
OTE^a
n/person-years^b	280/11,813	462/9,434
Rate/1,000 ^c	23.7 (21.1-26.7)	49.0 (44.6-53.7)
Rate ratio (after vs. before) ^d	--	2.1 (1.8-2.4)

^aVTE = venous thromboembolic events; RCC = renal cell cancer; DVT = Deep Vein Thrombosis; PE = Pulmonary Embolism; OTE = Other thromboembolic event. OTE category includes the following diagnoses: central retinal vein occlusion, venous tributary (branch) occlusion, Nonpyogenic thrombosis of intracranial venous sinus, phlebitis/thrombophlebitis of superficial vessels of lower extremities, phlebitis/thrombophlebitis of superficial veins of upper extremities, phlebitis/thrombophlebitis of other sites, gout with other specified manifestations, Budd-Chiari syndrome, and venous embolism/thrombosis of renal vein.
^bn = number of VTE events; p-y = person-years.
^cRates are per 1,000 person-years and are unadjusted. Age adjustment is unnecessary as these rates are intentionally representative of the older subpopulation (ages 65+) of RCC patients. Only first VTE counted in rate estimates.
^dRate ratios are unadjusted.

ISSN: 1471-2407